lopinavir/ritonavir in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Hung et al., 2020 (REV) 2.11 [0.04; 108.31]
Nojomi, 2020 2.04 [0.18; 23.27]
Nojomi, 2020 (REV) 2.04 [0.18; 23.27]
Solaymani-Dodaran, 2021 (REV) 0.82 [0.44; 1.51]
0.92 [0.52 ; 1.64 ] Hung et al., 2020 (REV), Nojomi, 2020, Nojomi, 2020 (REV), Solaymani-Dodaran, 2021 (REV) 4 0% 700 moderate not evaluable clinical improvementdetailed results Huang, 2020 (REV) 0.73 [0.39; 1.37]
Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
0.45 [0.16 ; 1.26 ] Huang, 2020 (REV), Hung et al., 2020 (REV) 2 73% 149 moderate not evaluable clinical improvement (14-day)detailed results Huang, 2020 (REV) 0.73 [0.39; 1.37]
0.73 [0.39 ; 1.37 ] Huang, 2020 (REV) 1 0% 22 NA not evaluable clinical improvement (time to event analysis only)detailed results Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
Solaymani-Dodaran, 2021 (REV) 1.06 [0.85; 1.33]
0.55 [0.14 ; 2.24 ] Hung et al., 2020 (REV), Solaymani-Dodaran, 2021 (REV) 2 90% 507 moderate not evaluable hospital dischargedetailed results Huang, 2020 (REV) 0.50 [0.29; 0.87]
0.50 [0.29 ; 0.87 ] Huang, 2020 (REV) 1 0% 22 NA not evaluable mechanical ventilationdetailed results Solaymani-Dodaran, 2021 (REV) 0.62 [0.32; 1.18]
0.62 [0.32 ; 1.18 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable radiologic improvement (14-day)detailed results Huang, 2020 (REV) 0.75 [0.53; 1.06]
0.75 [0.53 ; 1.06 ] Huang, 2020 (REV) 1 0% 22 NA not evaluable radiologic improvement (7-day)detailed results Huang, 2020 (REV) 0.42 [0.04; 3.91]
0.42 [0.04 ; 3.91 ] Huang, 2020 (REV) 1 0% 22 NA not evaluable viral clearance detailed results Huang, 2020 (REV) 0.83 [0.54; 1.29]
Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.46 [0.13 ; 1.63 ] Huang, 2020 (REV), Hung et al., 2020 (REV) 2 86% 149 moderate not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.23 [0.10 ; 0.54 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.54 [0.12; 2.48]
Huang, 2020 (REV) 0.92 [0.80; 1.06]
0.91 [0.79 ; 1.05 ] ELACOI (Lopinavir/ritonavir), 2020 (REV), Huang, 2020 (REV) 2 0% 91 moderate not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.92 [0.35; 2.47]
Huang, 2020 (REV) 0.83 [0.42; 1.67]
0.86 [0.49 ; 1.52 ] ELACOI (Lopinavir/ritonavir), 2020 (REV), Huang, 2020 (REV) 2 0% 91 moderate not evaluable ICU admissiondetailed results Solaymani-Dodaran, 2021 (REV) 0.81 [0.46; 1.44]
0.81 [0.46 ; 1.44 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 3.28 [0.79; 13.64]
3.28 [0.79 ; 13.64 ] ELACOI (Lopinavir/ritonavir), 2020 (REV) 1 0% 69 NA not evaluable serious adverse eventsdetailed results Hung et al., 2020 (REV) 4.28 [0.14; 130.10]
4.28 [0.14 ; 130.10 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable adverse eventsdetailed results Huang, 2020 (REV) 0.56 [0.04; 7.21]
0.56 [0.04 ; 7.21 ] Huang, 2020 (REV) 1 0% 22 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-21 02:55 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 509
- roots T: 290